Literature DB >> 7975564

Gene therapy for diseases of the nervous system.

J Fick1, M A Israel.   

Abstract

Advances in molecular biology and recombinant DNA technologies have contributed to our understanding of the molecular basis of many diseases. Now the possibility of gene transfer into normal cells to produce a gene product of therapeutic potential, or into diseased cells to correct the pathologic alteration, promises to revolutionize medical practice. In contemporary medicine, many therapeutic strategies focus on the link between a biochemical deficiency and the ensuing disorder. The treatment of noninfectious disease is often based on replacement therapy; medication is given to compensate for biochemical defects and to prevent or reverse the progression of disease. Although conventional therapies seldom alter the fundamental cause of a disease, gene therapy potentially could correct, at a molecular level, the genetic abnormalities contributing to its pathogenesis. Treatment directed at specific molecular alterations associated with the development of neurologic disease provides expectations of more effective and less toxic therapy. The development of gene therapy for nervous system tumors has progressed rapidly and may be prototypical in the development of therapies for inherited and acquired disorders of the nervous system. We describe possible strategies for using gene therapy to treat nervous system disorders, and we review recent advances in gene therapy for nervous system tumors.

Entities:  

Mesh:

Year:  1994        PMID: 7975564      PMCID: PMC1011407     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  43 in total

Review 1.  Progress toward human gene therapy.

Authors:  T Friedmann
Journal:  Science       Date:  1989-06-16       Impact factor: 47.728

Review 2.  Human gene therapy.

Authors:  W F Anderson
Journal:  Science       Date:  1992-05-08       Impact factor: 47.728

Review 3.  Genetically modified cells: applications for intracerebral grafting.

Authors:  F H Gage; M D Kawaja; L J Fisher
Journal:  Trends Neurosci       Date:  1991-08       Impact factor: 13.837

4.  Gene therapy for cancer.

Authors:  K Sikora
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

5.  In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy.

Authors:  W L Bi; L M Parysek; R Warnick; P J Stambrook
Journal:  Hum Gene Ther       Date:  1993-12       Impact factor: 5.695

Review 6.  Grafting genetically modified cells to the brain: possibilities for the future.

Authors:  F H Gage; J A Wolff; M B Rosenberg; L Xu; J K Yee; C Shults; T Friedmann
Journal:  Neuroscience       Date:  1987-12       Impact factor: 3.590

7.  Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy.

Authors:  F L Moolten
Journal:  Cancer Res       Date:  1986-10       Impact factor: 12.701

8.  Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene.

Authors:  Z D Ezzeddine; R L Martuza; D Platika; M P Short; A Malick; B Choi; X O Breakefield
Journal:  New Biol       Date:  1991-06

9.  In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors.

Authors:  K W Culver; Z Ram; S Wallbridge; H Ishii; E H Oldfield; R M Blaese
Journal:  Science       Date:  1992-06-12       Impact factor: 47.728

10.  Grafting genetically modified cells to the damaged brain: restorative effects of NGF expression.

Authors:  M B Rosenberg; T Friedmann; R C Robertson; M Tuszynski; J A Wolff; X O Breakefield; F H Gage
Journal:  Science       Date:  1988-12-16       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.